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doi:10.1016/j.ejvs.2010.01.028Abstract The autoimmune disease atherosclerosis contributes to several vascular complica-
tions. Besides vascular cells, inflammatory cells occur prominently in atherosclerotic lesions;
lymphocytes play a detrimental role in the initiation and progression of this common vascular
disease. Recent discoveries have led to the identification of several important lymphocyte
types within the atherosclerotic lesions. However, peripheral lymphocytes and those in the
lymphoid organs both figure critically in the regulation of atherosclerotic lesion growth.
Although the concept of atherosclerosis as an autoimmune disease is well known, the ways
in which autoantigens and autoantibodies contribute to atherogenesis in human or even in
animal models remains largely unknown. For example, autoantigen immunisation can either
promote or attenuate atherogenesis in animals, depending on the antigen types and the routes
and carriers of immunisation. This article summarises recent findings regarding lesion inflam-
matory cell types, autoantigens and autoantibody isotypes that can affect the initiation and
progression of atherosclerosis from both human and animal studies.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Atherosclerosis remains the most common cause of vascular
complications, including stroke, myocardial infarction (MI)
and aortic aneurysms. Data suggest that atherosclerosis
also constitutes an autoimmune disease, in which auto-
antigens and autoantibodies affect this vasculature
remodelling process. Processing and presentation of auto-
antigens and subsequent autoantibody production can525 4380.
vard.edu
ty for Vascular Surgery. Publisheoccur in lymphoid organs as well as in non-lymphoid tissues
such as aortas. In human atherosclerotic lesions, many cells
participate in this process, including lymphocytes, macro-
phages, dendritic cells (DCs), mast cells and even vascular
smooth muscle cells (SMCs) or endothelial cells (ECs)
(Fig. 1). Many of the inflammatory cells are recruited from
the lymphoid organs or the circulation and participate in
antigen or autoantigen presentation and T-cell activation.
This study discusses our current understanding of how
autoantigens and autoantibodies contribute to atheroscle-
rosis in human and animal models.d by Elsevier Ltd. All rights reserved.
Figure 1 Atherosclerotic lesion professional and non-professional antigen presenting cells and (auto)antigen-mediated T cell
activation.
486 G.-P. ShiInflammatory Cells in Atherosclerotic Lesions
The best-studied inflammatory cells in atherosclerotic
lesions include T cells, B cells, DCs and macrophages. Few
studies focus on other ‘minor’ inflammatory cells such as
mast cells and neutrophils. Besides T cells, all other inflam-
matory cells can present antigens (antigen presenting cells,
APCs) to assist T-cell activation, essential for the early
progression of atherosclerosis. In human or animal athero-
sclerotic lesions, T cells include mainly CD4þ and CD8þ cells,
although CD4þ cells dominate in number. It has been sug-
gested that T-cell activation occurs initially in lymphoid
organs such as spleen and lymph nodes and then migrates to
the aorta for secondary activation by APCs that present the
same antigens (Fig. 1). In turn, activated Tcells can stimulate
other inflammatory cells such as macrophages to secrete
inflammatory cytokines, proteases and tissue factors.1
CD4þ T cells contain two subsets: Th1 and Th2. In human
atherosclerotic lesions, Th1 cells expressing the cytokines
interferon-g (IFN-g) and interleukin 2 (IL2) prevail over IL4-,
IL5- and IL10-producing Th2 cells. T cells isolated from
human lesions produce a high amount of IFN-g but a low
amount of IL4.2 B cells, which occur in much fewer numbers
than T cells, appear in the fatty streak or the more external
layer of the aortic wall (Fig. 1).1 Both T and B cells play an
essential role in the pathogenesis. A reduction of T and B
cells can lead to decreased plaque development.1 With
CD4þ T-cell transfer from immunocompetent to immuno-
deficient apolipoprotein E knockout Apoe/ mice, disease
increases dramatically, whereas atherosclerosis-prone but
immunodeficient animals show reduced development of
early lesions with the fatty streaks.3 By contrast, low-
density lipoprotein receptor-deficient Ldlr/ micelacking B cells had 30e40% increase in atherosclerosis,
resulting in decreased serum anti-ox-LDL autoantibodies e
suggesting that the B cells that make autoantibodies are
anti-atherogenic. This explains why mice that go through
splenectomy have enhanced atherosclerosis, a phenom-
enon that splenic B-cell reconstitution can reverse.4
In contrast to B cells, DCs occur in the sub-endothelial
space with other immunocompetent cells. There, they
capture autoantigens then migrate to lymphoid stations,
where they present autoantigens to T cells, provoking their
responses.5 Thus, T cells isolated from human atheroma can
respond to specific autoantigens while DCs and macro-
phages can present such autoantigens, giving rise to clonal
expansion of their specific T cells and autoantibodies.
Compared with macrophages or lymphocytes, mast cells
constitute minor inflammatory cells in human atheroscle-
rotic lesions, although their low numbers do not indicate
insignificance. Mast cell inactivation reduces atheroscle-
rotic lesion development in Apoe/mice.6 Using mast cell-
deficient KitW-sh/W-sh mice, we demonstrated that these
minor inflammatory cells are indeed critical to diet-induced
atherosclerosis in Ldlr/ mice. KitW-sh/W-sh mice in the
background of Ldlr/ are protected from atherogenesis.
Using mast cell reconstitution techniques, we found that
mast cells release pro-inflammatory cytokines IL6 and IFN-g
to stimulate vascular cell release of matrix-degrading
proteases.7 Therefore, different inflammatory cells serve
different roles in atherogenesis.
Autoantigens
Autoantigens refer to those generated by structure modi-
fication on specific moieties of endogenous molecules.
Immunomodulation of Vascular Diseases 487Although these antigens occur in human atherosclerotic
lesions, they are not aorta-specific. In atherosclerotic
lesions, oxidised LDL (ox-LDL), heat-shock proteins (HSPs)
and b2-glycoprotein I (b2-GPI) are the most common
autoantigens.
In early atherosclerotic lesions, LDLs are trapped in the
sub-endothelial space and subsequently oxidised.8 Two
aldehydes with strong immunogenic properties develop:
malondialdehyde (MDA) and 4-hydroxynonenal aldehyde
(Fig. 2A and B) with anionic valence. This oxidation process
associates with major structural modifications of LDL,
including fragments of apo B-100 and generation of various
aldehyde and phospholipid adducts to apo B-derived
peptides. DCs and macrophages uptake ox-LDL and use
major histocompatibility complex (MHC) class II molecules
to present ox-LDL for recognition by specific CD4þ T cells
and then lead to ox-LDL-specific T-cell expansion.9 Indeed,
about 10% of lesional T cells are ox-LDL-specific,9 which
also appear in circulation. Transfer of ox-LDL-reactive T
cells to T-cell-deficient Apoe/scid/scid mice occurs more  Malondialdehyde   
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Figure 2 Chemical structures of common autoantigen modific
cardiolinpin.efficiently at lesion acceleration than transfer of T cells
without antigen specificity.10 Besides stimulating T cells via
APCs, ox-LDL can promote inflammation by attracting
monocytes and more T cells to the lesions. Ox-LDL can also
be cytotoxic to the ECs (causing a prothrombotic endo-
thelial surface dysfunction) and stimulate the release of
various soluble inflammatory and adhesion molecules.
Macrophage scavenger receptors (SRs) remove ox-LDL,
leading to ox-LDL macrophage intracellular accumulation
and foam cell formation. Clinical studies showed the pres-
ence of IgM against MDA-modified apo B-100 peptide and
association with plasma ox-LDL levels in humans.11
Autoantigen HSP shows high-sequence homology from
bacteria to humans. For example, mycobacterial and
chlamydial HSP65 show considerable mimicry with human
HSP60.12 Most known risk factors or stressors evoke HSP
expression on ECs, SMCs and macrophages to maintain cell
viability. In turn, HSP induces production of inflammatory
cytokines and proteases from macrophages and mediates
monocyte adhesion to the endothelium. In subjects with-glycero-3-phosphorylcholine 
lipin) 
ation moieties or antigenic epitopes (AeD). E. Autoantigen
488 G.-P. Shiestablished cardiovascular disease (CVD), antibodies
against HSP60/65 increase and predict further development
of the disease.13 These antibodies specifically react with
cells in the plaques and mediate lysis of stressed ECs and
macrophages. Chlamydial HSP65 isolated from human
serum are cytotoxic to heat-stressed human ECs, and
antibodies to microbial HSP65 recognise specific epitopes
on human HSP60 present in the arterial wall of healthy
young people.12 Intralesional cells have significantly
increased T-cell reactions against human HSP60 compared
with peripheral T cells, and T cells isolated from human
atherosclerotic lesions showed significant reaction against
human HSP60 as well as chlamydial and mycobacterial
HSP.14 On challenge with human HSP60, plaque T cells
express Th1 functions, including cytotoxicity and monocyte
tissue factor production.14
High levels of autoantigen b2-GPI alongside CD4þ and
CD8þ T cells appear in atherosclerotic lesions. b2-GPI binds
strongly to negatively charged molecules such as phospho-
lipids and to activated platelets and apoptotic cell
membranes, which mediate clearance of apoptotic cells
from the circulation. In atherosclerotic lesions, b2-GPI
colocalises with ox-LDL and often forms covalent complexes
that occur in autoimmune diseases. In patients with systemic
lupus erythematosus (SLE) or anti-phospholipid syndrome
(APS), serum complexes and anti-b2-GPI-ox-LDL complex
autoantibodies are elevated.15 Similarly, such complexes
and antibodies present in the bloodstream of patients with
vascular complications, such as MI and unstable angina,
strongly associate with arterial thrombosis. These
complexes inhibit ox-LDL uptake by macrophages through
SRs, but aremore rapidly internalised bymacrophages as IgG
immune complexes in the presence of anti-b2-GPI autoan-
tibodies. These macrophages will then present b2-GPI anti-
genic peptides (onMHC class II) to specific Tcells. Therefore,
circulating IgG immune complexes containing ox-LDL and b2-
GPI can be pro-atherogenic. Indeed, adoptive transfer of b2-
GPI-reactive lymphocytes enhances early atherosclerosis in
Ldlr/ mice.16
Autoimmune Diseases and Atherosclerosis
Atherosclerosis shares many similarities with other chronic
autoimmune diseases such as SLE, rheumatoid arthritis
(RA), APS, vasculitis and type I diabetes. They all have
evidence of activation of macrophages, lymphocytes and
ECs; alteration in the Th1/Th2 ratio; and elevation of
inflammatory cytokines. Vascular inflammation in autoim-
mune diseases may cause LDL oxidation and interaction of
ox-LDL with various plasma proteins such as b2-GPI. These
events may favour autoantibody production and accelerate
arterial thrombosis.
Patients with SLE, a chronic autoimmune inflammatory
disease, are 5e6 times more likely to have coronary events
than the normal population. In young women, the risk can
increase to 50-fold.17 A large case-control study of non-
hospitalised SLE patients with no signs of renal failure
showed that the presence of plaques was much more
common among SLE patients than among controls. A recent
case-control study indicated that coronary artery calcifi-
cation was also more frequent in patients with lupus than in
controls.18 Anti-ox-LDL antibody titres associate withdisease activity in SLE. Increased atherosclerosis was also
found in lupus mice. Lupus-susceptible Ldlr/ mice
develop atherosclerosis under moderate dyslipidaemia
(chow diet), and overt accumulation of atherogenic lipo-
proteins can enhance SLE disease.19
RA, another prototypic autoimmune disease, also asso-
ciates with accelerated vascular risk, resulting in early
mortality and excess morbidity. RA patients can have up to
double the risk of a cardiovascular event irrespective of the
traditional CVD risk factors. Many of the same cells that
comprise the inflammatory infiltrates in an RA joint lining
are likewise found in the atherosclerotic plaques. Both
aberrant cellular and humoral immune responses are inte-
gral to the pathogenesis of the two conditions. The immune
dysregulation that characterises RA seems to have a key
role in the accelerated form of atherosclerosis present in
this autoimmune disease.20 Examination of carotid intimal
thickening (IMT) shows greater values of IMT in RA patients
than in controls. A recent study also showed an association
between ox-LDL autoantibodies and CVD in RA.21
One in three APS patients develops arterial thrombosis
(e.g., MI, stroke and angina) during the disease evolution.22
b2-GPI appears to constitute the major antigenic target for
anti-phospholipid antibodies and plays a central role in the
development of clinical complications of APS.
Vasculitis is a chronic inflammatory disease of the large
(aorta, coronary, pulmonary and cervical arteries), medium-
sized (subclavian, mesenteric, iliac and temporal arteries)
and small (skin, intestine, kidney, respiratory tract, etc.)
vessels. Like atherosclerotic lesions, vasculitic lesions also
contain T cells, monocytes, DCs and mast cells. These pro-
inflammatory cells are critical to the pathogenesis. For
examples, depletion of DCs abrogates large-vessel vasculitis
whereas stimulation of these cells in normal temporal
arteries induces vasculitis.23 Similar to atherosclerotic
patients, those with large-vessel vasculitis show high lesion
CD4þCD28 Th1 cell contents while defect in regulator T
cells (Treg) and their serum matrix metalloproteinase (MMP)
levels often increase, but anti-inflammatory IL10 decreased
compared to control subjects.24 Like other autoimmune
diseases, vasculitis often associates with increased IgG
autoantibodies against ox-LDL, HSPand b2GP-1.25e27 Besides
those inflammatory signatures, vasculitic patients demon-
strate endothelial cell injury, high IMT, arterial stiffness or
thoracic dilatation. Therefore, patients with vasculitis have
high risk of developing atherosclerosis. Indeed, both pop-
ulations share similar risk factors, such as diabetes, hyper-
tension and high serum levels of CRP and IgG autoantibodies
against ox-LDL, HSP and b2-GPI (Table 1).
Autoantigen Immunisation and Atherosclerosis
Prevention
Autoantigen immunisation-associated atherosclerosis is
probably one of the most difficult phenomena to under-
stand. The same autoantigens may yield controversial
atherosclerosis phenotypes if different immunisation
protocols were used (Table 2). Atherosclerosis-prone mice
receiving mucosal (oral or intranasal) immunisation of the
autoantigens ox-LDL, HSP or b2-GPI without adjuvant
demonstrated reduced atherosclerosis. Mouse lesions had
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Immunomodulation of Vascular Diseases 489fewer numbers of macrophages and CD4þ cells and IFN-g
staining. Mechanistically, autoantigen mucosal immunisa-
tion induces antigen-specific Treg and adaptive immune
cells to produce anti-inflammatory IL4, IL10 and trans-
forming growth factor beta (TGF-b) to inhibit plaque
inflammation and thus the progression of atherosclerosis
and reduction in the reactivity of lymph node lymphocytes
against autoantigens.28 Strong evidence indicates that Treg
participate in both early and advanced stages of athero-
sclerosis, particularly in preventing and/or reversing plaque
instability. Treg can be activated by rapamycin, anti-CD3
monoclonal antibodies or indirectly via DC activation.
Naive CD4þ T cells express CD25 and forkhead boxP3
(FoxP3) after incubation with rapamycin-treated and
HSP60-loaded DC, and display antigen specificity. Adoptive
transfer of these HSP60-specific CD4þCD25high T cells
inhibited plaque formation in Apoe/ mice.29 Treg cell
activation requires CD28-CD80/CD86 co-stimulation. Defi-
ciency of these co-stimulatory molecules or depletion of
CD25 using CD25-neutralising antibodies leads to increased
atherosclerosis.30
Complete Freund’s adjuvant (CFA)-mediated immunisa-
tion of autoantigen MDA-LDL (primary subcutaneous
immunisation in CFA followed by subsequent immunisation
in incomplete Freund’s adjuvant, IFA) also yielded
decreased atherosclerotic lesion sizes in Watanabe heri-
table hyperlipidaemic rabbits and in Ldlr/ mice,31,32 but
through different mechanisms from those of mucosal
immunisation (Table 2). CFA-mediated immunisations of
MDA-LDL or its fragments of human apo B-100 produce
a T-cell-dependent increase in the titres of autoantibodies
against MDA-LDL and great reduction of atherosclerosis in
Apoe/ mice with increased IgG1 (Th2 specific). Such
atheroprotective effects of autoantigen immunisation
occur independently of adjuvant, regardless of whether
using Freund’s adjuvant (FA) or cationised bovine serum
albumin (BSA) and aluminium.31e47 Injection of high-dose
ox-LDL in neonatal Apoe/ mice without adjuvant also
reduced atherosclerosis and resulted in suppression of the
T-cell response against ox-LDL.39 These findings concur with
the observations that patients with MI have lower levels of
MDA-LDL autoantibodies, supporting the notion that anti-
bodies to autoantigens are atheroprotective. This conclu-
sion is not only true in ox-LDL-immunised animals, but also
in animals receiving pathogenic bacteria, which also act
through increased ox-LDL autoantibodies. Binder et al.
demonstrated that Streptococcus pneumoniae immunisa-
tion resulted in increased ox-LDL autoantibody T15 titre
and concomitant reduction in atherosclerotic lesion size in
Ldlr/ mice after a similar immunisation protocol to those
of MDA-LDL discussed above.31,32,40 In addition to increased
T15 titre, pneumococci-immunised mice also displayed
increased in vivo formation of circulating IgM immune
complexes with apo B-containing particles. Treatment with
anti-phosphorylcholine IgM isolated from a T15 idiotype
hybridoma reduced vein graft atherosclerosis in Apoe/
mice, suggesting the importance of phosphorylcholine
moiety (Fig. 2C) on autoimmunogens. In supporting this
hypothesis, immunisation with phosphorylcholine-coupled
keyhole limpet haemocyanin (KLH) associates both with
a threefold increase in specific antibodies and a 40%
reduction in atherosclerosis at the aortic root, even using
Table 2 Immunization-mediated anti- and pro-atherogenesis in animal models.
Antigen Immunisation Protocol Carrier/Adjuvant Animal (sex) Induction of atherosclerosis Reference
Anti-atherogenic immunisation:
Human ox-LDL Oral immunisation none Ldlr/ Mice
(unknown gender)
Atherogenic diet 33
Mycobacterium HSP65 Oral or Nasal immunisation none Ldlr/ Mice (female) M. tuberculosis immunisation
in IFA or atherogenic diet
34,35
Human or bovine b2-GPI Oral immunisation none Ldlr/ Mice (female) Atherogenic diet 36
WHHL rabbit MDA-LDL Subcutaneous immunisation CFA and IFA WHHL rabbit
(both genders)
Atherogenic diet 31
Murine MDA-LDL Subcutaneous immunisation CFA and IFA Ldlr/ Mice (female) Atherogenic diet 32
Human apo B-100 peptide-45,
-74, -143, -210, or -240
Subcutaneous
immunisation
cationized BSA
/aluminium
Apoe/ mice (male) Atherogenic diet 37,38
Human ox-LDL Intraperitoneal
injection
none neonatal Apoe/ mice
(both genders)
Atherogenic diet 30
S. pneumoniae Subcutaneous
immunisation
CFA and IFA or
none
Ldlr/ mice (both genders) Atherogenic diet 40
Phosphorylcholine-KLH Intraperitoneal immunisation Oligonucleotide
CpG
Apoe/ (female) Chow diet 41
None Subcutaneous immunisation Aluminium
hydroxide
Apoe/ (male) Chow diet 42
Pro-atherogenic immunisation:
Human b2-GPI Subcutaneous immunisation CFA Ldlr/ or Apoe/ mice
(female)
Chow or atherogenic diet 43,44
Recombinant HSP65 or
M. tuberculosis
Subcutaneous immunisation IFA C57BL/6J mice (female) Atherogenic diet 45
Recombinant HSP65 or
M. tuberculosis
Subcutaneous immunisation IFA Ldlr/ mice (female) Chow diet 46
Mycobacterium HSP65 Intracutaneous injections CFA and IFA NZW rabbits (male) Chow or atherogenic diet 47
Abbreviations: WHHL: Watanabe heritable hyperlipidemic; NZW: New Zealand White; KLH: keyhole limpet hemocyanin; CFA: complete Freund’s adjuvant, IFA: incomplete Freund’s
adjuvant; BSA: bovine serum albumin.
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Immunomodulation of Vascular Diseases 491oligonucleotide CpG as adjuvant,41 which does not possess
intrinsic atheromodulating properties. Therefore, stimula-
tion of the immune response against oxidised phospholipids
represents one possible approach for the development of
an immunomodulatory therapy for atherosclerosis.
Importantly, not all autoantigen immunisations yield
atheroprotective phenotypes. Immunisation of Apoe/ or
Ldlr/ mice with b2-GPI induced an increase of athero-
sclerosis.43,44 Similarly, parental immunisation of Ldlr/
mice or normocholesterolaemic rabbits with mycobacterial
HSP65 in IFA results in the development of atherosclerosis,
and T cells isolated from these plaques respond specifically
to HSP65 in vitro (Table 2).46,47 Transfer of HSP65-reactive
cells also accelerates disease in hypercholesterolaemic
animal models. Of importance, when CFA (containing
mineral oil and heat-killed mycobacterial HSP65) is injected
into non-hypercholesterolaemic animals, atherosclerotic
lesions develop in the aorta, principally in sites exposed to
an elevated haemodynamic stress.48 Such adjuvant-
initiated atherosclerosis did not occur in IFA-immunised
animals, likely due to the lack of mycobacterial HSP65
contaminations in IFA. Therefore, selection of the adjuvant
in autoantigen immunisation can prove critical to athero-
sclerosis outcomes.Autoantibodies and Atherosclerosis
Immunisation of atherosclerosis-prone animals with ox-LDL,
regardless of adjuvant selection, demonstrated the impor-
tance of autoantibodies in atherosclerosis animal mod-
els.31e39 The most extensively characterised anti-ox-LDL
autoantibody is an IgM called EO6, which reacts against
an oxidised phospholipid in modified LDL that has been
identified as 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-
phosphorylcholine (Fig. 2D). Palinski et al.49 first cloned
this ox-LDL monoclonal antibody that recognises the phos-
phorylcholine epitope in oxidised phospholipids and those
on apoptotic cell surfaces from B-cell hybridoma from
Apoe/ mice. This autoantibody is indistinguishable from
the natural antibody T15, which is secreted by a specialised
subclass of B lymphocytes termed B-1 cells in the peritoneal
cavity and spleen. Functionally, these autoantibodies block
the selective binding to ox-LDL and apoptotic cells by SRs in
a dose-dependent manner and thereby prevent macro-
phage lipid accumulation. In addition to IgM, IgG also
inhibits ox-LDL uptake by macrophages. In MDA-LDL-
immunised Apoe/ mice, the IgG titres against MDA-LDL
correlate inversely with plaque size and serum cholesterol
levels.50 These antibodies neutralise the many pro-
atherogenic effects of ox-LDL and minimally oxidised LDL
and inhibit apoptotic blebs to induce monocyte adhesion by
ECs. In humans, antibodies present in the plasma target
a series of MDA-modified peptide sequences in apo B-100.
Clinical studies indicated that IgM against MDA-LDL and ox-
LDL associated inversely with carotid or femoral IMT, and
IgG against ox-LDL also correlated inversely with carotid
IMT. In a nested case-control study, these IgM predicted the
risk of developing acute MI and causing cardiac death.11
By contrast, anti-bacterial HSP65 antibody levels corre-
late positively with the presence of sonographically visible
atherosclerotic lesions in the carotid arteries andestablished coronary atherosclerosis, and associate with
elevated levels of coronary calcification independent of
established coronary artery disease (CAD) risk factors.
A subsequent follow-up study confirmed that such correla-
tion held true in a 5-year period of observations, especially
in those with progressive carotid atherosclerosis.13 Human
serum HSP65 antibodies react with recombinant form of
human HSP60 and those present in ECs, macrophages and
SMCs in atherosclerotic lesions. Purified anti-HSP65 anti-
bodies are indeed cytotoxic to ECs. Similarly, antibodies
targeting human HSP60 also associate with severity of CAD.
Increased levels of soluble HSP60 and antibodies to HSP60
predict increased risk of CAD. A large population-based
study showed the presence of serum soluble HSP60 in
patients with carotid atherosclerosis, a correlation that
held independent of age, sex and other risk factors.51
Bacterial infection-associated atherosclerosis has been
linked to HSP60/65. Anti-HSP60 antibody correlates strongly
with human IgA to Chlamydia pneumoniae and with IgG to
Helicobacter pylori. Infection with C. pneumoniae showed
pro-atherogenic effect. Research suggests that bacterial
HSP60 product exerts a direct pro-atherogenic effect by
stimulating TNFa and MMP production52 and IgA anti-HSP60
and anti-C. pneumoniae increases the risk of coronary
events seven times.53 Serum IgG antibody against particular
sequences of the H. pylori-derived HSP60 appeared
predominantly in CVD patients. H. pylori infection induces
atherosclerosis in mice by causing autoimmunity to endog-
enous HSP60 due to molecular mimicry and enhancing HSP-
specific Th1 immune responses. Antibiotics or anti-HSP60
antibodies reduce atherosclerosis in these mice.54
Similar to antibodies to HSP60/65, those against auto-
antigens b2-GPI or cardiolipin (Fig. 2E) also positively
correlate with cardiovascular events. Case-control studies
demonstrated the association of anti-cardiolipin antibodies
(aCLs) with stroke and acute MI,55 and IgG/IgM/IgA aCL and
IgA for anti-b2-GPI associate with increased risk of ischae-
mic stroke, arterial thrombosis, atherosclerotic immune
process, acute MI and peripheral vascular diseases.
Although the exact mechanisms remain unknown, anti-b2-
GPI was thought to interact with b2-GPI on EC membrane
and induce pro-inflammatory and procoagulant endothelial
phenotype that is pro-atherognic.56Autoantigen-Associated Clinical Trials
As discussed in Table 2, several promising observations were
made from animal studies using autoantigen mucosal
immunisation or parental immunisation with oxidisation-
modified antigens. These data suggest the possibility of
using the same approaches in human atherosclerosis
prevention. Although direct application of the same immu-
nisation protocol in treating human atherosclerosis is waiting
to be developed, autoantigen HSP mucosal immunisation or
vaccination did prove effective in patients with other auto-
immune diseases (e.g., RA and type I diabetes) or in different
cancer patients (Table 3). As we discussed above (Table 2),
animals receiving ox-LDL immunisation demonstrated anti-
atherogenic phenotype mainly by increasing anti-ox-LDL
antibodies, suggesting the possibility of using anti-ox-LDL
as a therapy for human atherosclerosis. Indeed, a phase II
Table 3 Few selected atherosclerosis autoantigen-related clinical trials.
Antigen and protocol Status Reference or institution information
HSP oral immunisation,
once a day, 6 month
Safe, developed tolerogenic T cell response,
showed reduced TNFa, increased IL10, and improved RA
57
dnaJP1 (HSP peptide),
oral, once a day
Phase II trial for RA, achieved >40% ACR20
response and 80% reduction of in vitro T cell
TNFa production and increase in tolerogenic
cytokines IL10 and FoxP3; ready for phase III trial
Adeona Pharmaceuticals, Inc.
Ann Arbor, MI
DiaPep277 (HSP peptide),
subcutaneous injection
Phase II trial for type I diabetes, preserved
endogenous insulin production
58
HSP peptide p27 and p35 Phase I clinical trial for type I diabetes Hadassah University Hospital,
Jerusalem, Israel
HSP96 vaccine Phase III on melanoma, showed 29% survival extension 59
HSP70 vaccine Phase I trial on genital herpes 59
HSP65 vaccine Phase II trial on intraepithelial neoplasia,
showed >50% reduction
59
HSP65 vaccine Phase II trial on cervical intraepithelial neoplasia 59
Anti-ox-LDL Phase II clinical trial on cardiovascular diseases Genentech, Inc. South
San Francisco, CA
*ACR20: a composite endpoint developed by the American College of Rheumatology and accepted as an US Food and Drug Administration
approvable scoring criteria.
492 G.-P. Shiclinical trial using this strategy has been initiated by Gen-
entech, Inc., South San Francisco, California.
It is intriguing that Apoe/ mice receiving aluminium
hydroxide subcutaneous immunisation without any antigen
had reduced atherosclerosis compared with those that
received saline alone, presumably via down-regulated
T-cell activation but increased Treg activity.
42 Indeed,
aluminium hydroxide is the most common vaccine adjuvant
in both humans and animals.60 It is primarily used in
tetanus, diphtheria, pertussis and poliomyelitis due to its
confirmed safety. Therefore, it is possible that aluminium
hydroxide vaccination without any antigen may be used in
treating human atherosclerosis.
Together, different autoantigens, autoantibodies and
bacterial infections can either promote or protect against
atherogenesis e depending on the type of antigens, anti-
bodies, bacterial strains and even immunisation protocols
withmechanismsmore complicated thanwe currently know.
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